Edition:
United States

Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

Morphosys AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

27 Aug 2016 Reuters Investment Profile 12 $20.00

Wright Investors Service Comprehensive Report for MorphoSys AG

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio table...

22 Aug 2016 Wright Reports 61 $75.00

MorphoSys AG (MOR) - Financial Analysis Review

MorphoSys AG (MOR) - Financial Analysis Review Summary MorphoSys AG (Morphosys) is a pharmaceutical company that develops mon...

17 Aug 2016 GlobalData 80 $300.00

"The Economy Matters" Report for MPSYF: the economy's impact on MPSYF's price and risk, featuring the powerful Economic Climate Rating and the new MacroRisk "Stoplight" and Risk Correspondence Score

"The Economy Matters"(r) Reports feature the powerful Economic Climate Rating and MacroRisk "Stoplight" to help you in your a...

16 Aug 2016 MacroRisk Analytics/EconomicInvestor 8 $25.00

Is There Long-Term Value in MorphoSys AG?

12 Aug 2016 Sadif Analytics Prime 12 $25.00

MorphoSys AG (FSE- MOR)

MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully a...

10 Aug 2016 Acquisdata 11 $15.00

MORG.DE - Event Transcript of Morphosys AG conference call, Aug. 01, 2016 / 8:00AM ET

Edited Event Transcript of MORG.DE conference call, Aug. 01, 2016 / 8:00AM ET Boston, Aug 1, 2016 (Thomson StreetEvents...

01 Aug 2016 Thomson Reuters StreetEvents 10 $75.00

MorphoSys AG: Downgraded to Average

21 Jun 2016 Sadif Analytics Prime 3 $10.00

MorphoSys AG (MOR) - Financial Analysis Review

MorphoSys AG (MOR) - Financial Analysis Review Summary MorphoSys AG (Morphosys) is a pharmaceutical company that develops mon...

17 Jun 2016 GlobalData 77 $300.00

Bimagrumab (noch?) nicht erfolgreich – F&E-Arbeit mit 104 Projekten auf Rekordniveau

Der therapeutischen Antikörper Bimagrumab von Partner Novartis erreichte in einer Ph 2b/3-Studie in sIBM nicht den primären P...

17 May 2016 EQUI.TS 4 $10.00